News

The randomized, double-blind, placebo-controlled Phase 2 study will be conducted across 50 sites in Europe, the U.S., Canada, Israel, and Turkey, and enroll approximately 260 patients. The Company

AC Immune CEO Prof Andrea Pfeifer said: “We are delighted with the progress of ACI-24, the anti-Abeta vaccine, derived from our proprietary SupraAntigenTM platform. In addition to the

The approval follows the priority review of Alecensa in China, just eight and nine months after European Medicines Agency (EMA) and US Food and Drug Administration (FDA) approvals,

Approval for this indication has been granted under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be

In their study in mice, the scientists discovered that liver injury triggered senescence, which is normally associated with aging or chronic disease. The researchers found that certain anti-cancer

The study, the first programme under Immunocore’s collaboration with GSK to proceed into clinical development, will assess the safety and tolerability of IMCnyeso in patients with non-small cell

The partnership will carry out clinical trial to explore the potential of combination therapy with AbbVie’s venetoclax and Tolero’s investigational agent alvocidib to treat relapsed/refractory AML. Alvocidib is

Through a multi-phase collaboration, WuXi will leverage and evaluate Cyclica’s cloud-based proteome Ligand Express screening platform to investigate the off-target profiles of small molecules, apply Cyclica’s novel and

At the week 16 primary efficacy analysis, the study met both co-primary endpoints and all key secondary endpoints. Fasinumab-treated patients experienced significantly less pain and significantly improved functional